New drug aims to deepen remission in multiple myeloma

NCT ID NCT01242930

Completed Disease control Sponsor: Geron Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat intravenously, and some also continued lenalidomide maintenance. The study measured response improvement, progression-free survival, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: imetelstat (GRN163L)
What this could lead to: If successful, imetelstat could help improve disease control in multiple myeloma patients who have not achieved a complete response after initial treatment.
What could go wrong: This is a small, early-phase trial with only 13 participants, so results may not apply broadly. The drug may not improve response rates or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Sidney Kimmel Cancer Center Johns Hopkins Hospital

Baltimore, Maryland, 21231, United States
University of Maryland Medical Center - M & S Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.